Obulytix joins INCATE to accelerate clinical and strategic development of precision biologics

Obulytix has joined INCATE (INCubator for Antibacterial Therapies in Europe), a European initiative supporting innovative companies developing solutions at the intersection of serious disease care and antimicrobial resistance (AMR).

Through INCATE, high-potential innovators gain access to expert guidance, strategic support and cross-sector networks aimed at accelerating the development of novel therapies that address urgent unmet medical needs.

For Obulytix, participation in INCATE represents an important step in advancing its Precision Lysin Therapeutics (PLTs), a new class of engineered biologics designed to selectively kill bacteria through a novel mechanism, without fuelling antimicrobial resistance.

Supporting next-stage development

Obulytix is currently advancing PLTs for the treatment of bloodstream infections caused by multidrug-resistant Acinetobacter baumannii, one of the most dangerous hospital-associated pathogens and a priority threat in intensive care settings.

By joining INCATE, Obulytix aims to strengthen several key areas of development, including:

• Non-clinical and early clinical development strategy

• Regulatory pathways and expedited review opportunities

• Market access, pricing and reimbursement strategy

• Access to specialist expertise and strategic networks

• Strengthening investor readiness for future growth stages

Addressing infections in vulnerable patient populations

Serious bacterial infections remain a major risk in medically vulnerable populations, including hospitalized and immunocompromised patients. When resistance limits treatment options, the impact on clinical outcomes, healthcare burden and survival can be substantial.

Obulytix develops targeted antibacterial biologics designed to address these high-need settings, with the potential for faster bacterial clearance, reduced resistance pressure and scalable manufacturing.

Building the future of AMR innovation

Participation in INCATE aligns with Obulytix’s broader mission to bring precision antibacterial innovation from platform stage to clinical reality.

By combining scientific progress with strong development planning, regulatory alignment, and strategic partnerships, Obulytix continues to build toward a new generation of therapies for multidrug-resistant infections.

For more information about INCATE, visit: https://www.incate.net/